A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT03626688 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

687

Enrollment

INDUSTRY

Sponsor class

Conditions

PAH
Pulmonary Hypertension
Pulmonary Arterial Hypertension
Hypertension
Connective Tissue Diseases
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Disease

Interventions

DRUG: Ralinepag
DRUG: Placebo

Sponsor

United Therapeutics